Research Overview
High Throughput Drug Screening - Allaying Risks Associated with Drug
Discovery
The development of effective drugs remains a challenging, risky and expensive
endeavour. High throughput drug screening (HTS) is emerging as a saviour in the
field of drug discovery as pharmaceuticals and biotechnology companies compete
to become the first to market new drugs. By shortening the drug discovery cycle,
HTS offers the opportunity to capture the maximum market share and optimise
revenue generation within the first year of entry. HTS also increases the
chances of clearing clinical trials by addressing issues related to
pharmacokinetics, animal toxicity and side effects. In spite of high equipment
costs and poor quality of lead compounds presenting a significant challenge, HTS
has the potential to yield both mechanistic insights and new drug leads with
unparalleled efficiency through investment and innovation.
This Frost & Sullivan research evaluates the key drivers and challenges
in the European HTS market. It also examines the important technology trends and
provides strategic recommendations for designing high-impact action plans.
Outsourcing HTS to Custom Screeners Proving Extremely Cost-effective
Outsourcing HTS has emerged as a cost-effective option for multinational
pharmaceuticals and biotechnology companies that are under pressure to discover
and develop new therapeutics at lesser costs and within shorter time frames.
Research indicates that approximately 10 per cent of the funds allocated to
early stage discovery are accounted for by outsourcing. "Outsourcing not
only compresses the time line for drug development and reduces the overall
costs, it also provides access to additional drug entities and innovative
technology," explains the analyst of this research.
Market for HTS is Expanding
The HTS field continues to be highly dynamic and competitive.
"Information sharing between competing companies, coupled with open
technology transfer meetings and publications, has greatly accelerated the
development of the HTS industry," says the analyst. The success of genomic
and proteomic searches provides a more comprehensive list of cellular targets.
The anticipated use of functional genomics and proteomics to bridge the gap
between physical-chemical activities and the drug development process is also
expected to be a major driver in the HTS market.
Frost & Sullivan Growth Partnership Service
Based on extensive and in-depth research, real-world consulting work, and new
theories tested in hundreds of companies across many industries, Frost &
Sullivan has evolved its Growth Partnership Services (GPS) programme that
provides established and emerging firms with powerful growth visions. Moving
beyond token mission statements, GPS provides an actionable vision to growth
consulting partners by illustrating how key intelligence and strategic research
based on defined goals can guide day-to-day behaviour and overall company
direction. The foundation of Frost & Sullivans GPS includes:
- Assisting companies to reach their full potential in the core business
- Providing growth strategies to help companies expand into related
businesses
- Preemptively redefining the core business during market turbulence
- Applying the Frost & Sullivan framework to identify and address common
mistakes resulting from misaligned corporate strategies
- Recommending growth management strategies through continuous partnership
To maximise the potential for growth within a firms internal and external
environment, Frost & Sullivan consultants can facilitate the creation of
strategic programmes that deliver improved market success. Frost &
Sullivans strengths lie in combining strategic understanding with market
expertise and applying these with absolute commitment to its clients growth.
View Cart
